You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSalicylate-sodium
Accession NumberDB01398
TypeSmall Molecule
GroupsApproved
Description

Sodium salicylate is a sodium salt of salicylic acid. It can be prepared from sodium phenolate and carbon dioxide under higher temperature and pressure.

It is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID) and induces apoptosis in cancer cells. It is also potential replacement for aspirin for people sensitive to it.

Structure
Thumb
Synonyms
SynonymLanguageCode
SalsoninNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS numberNot Available
WeightAverage: 160.1026
Monoisotopic: 160.013638701
Chemical FormulaC7H5NaO3
InChI KeyABBQHOQBGMUPJH-UHFFFAOYSA-M
InChI
InChI=1S/C7H6O3.Na/c8-6-4-2-1-3-5(6)7(9)10;/h1-4,8H,(H,9,10);/q;+1/p-1
IUPAC Name
sodium 2-hydroxybenzoate
SMILES
[Na+].OC1=CC=CC=C1C([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic alkali metal salt
  • Organic sodium salt
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIt is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID)
PharmacodynamicsNon-steroidal anti-inflammatory drugs such as Salicylate-sodium work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid to prostaglandin H2 (PGH2). PGH2, in turn, is converted by other enzymes to several other prostaglandins (which are mediators of pain, inflammation, and fever)
Mechanism of actionSalicylate-sodium is considered a non-selective COX inhibitor—that is, it inhibits two isoforms of cyclooxygenase, COX-1 and COX-2. The analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appears to be achieved mainly through inhibition of COX-2, whereas inhibition of COX-1 would be responsible for unwanted effects on platelet aggregation and the gastrointestinal tract. However, the role of the individual COX isoforms in the analgesic, anti-inflammatory, and gastric damage effects of NSAIDs is uncertain and different compounds cause different degrees of analgesia and gastric damage. Salicylate-sodium directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9253
Blood Brain Barrier+0.8725
Caco-2 permeable+0.8102
P-glycoprotein substrateNon-substrate0.8015
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9938
Renal organic cation transporterNon-inhibitor0.9134
CYP450 2C9 substrateNon-substrate0.7949
CYP450 2D6 substrateNon-substrate0.9035
CYP450 3A4 substrateNon-substrate0.7619
CYP450 1A2 substrateNon-inhibitor0.9298
CYP450 2C9 substrateNon-inhibitor0.9595
CYP450 2D6 substrateNon-inhibitor0.95
CYP450 2C19 substrateNon-inhibitor0.8808
CYP450 3A4 substrateNon-inhibitor0.9693
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9586
Ames testNon AMES toxic0.9448
CarcinogenicityNon-carcinogens0.854
BiodegradationReady biodegradable0.9624
Rat acute toxicity2.3171 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9461
hERG inhibition (predictor II)Non-inhibitor0.9832
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Sodium salicylate crystals0.09USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility48.1 mg/mLALOGPS
logP1.36ALOGPS
logP1.98ChemAxon
logS-0.52ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
AcarboseMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
AcenocoumarolMay enhance the anticoagulant effect of Vitamin K Antagonists. Exceptions: Salsalate.
AcetazolamideMay enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.
Acetylsalicylic acidAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
AlbiglutideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
AlogliptinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
AlteplaseMay enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
Aminosalicylic AcidMay enhance the anticoagulant effect of other Salicylates.
Ammonium chlorideAmmonium Chloride may increase the serum concentration of Salicylates.
AnagrelideAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
ApixabanMay enhance the anticoagulant effect of Anticoagulants.
ArgatrobanMay enhance the anticoagulant effect of Anticoagulants.
BenazeprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
Bismuth SubsalicylateMay enhance the anticoagulant effect of other Salicylates.
BivalirudinMay enhance the anticoagulant effect of Anticoagulants.
BromocriptineMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
BumetanideMay diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.
CanagliflozinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
CaptoprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
ChlorpropamideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
CilazaprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
CilostazolAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
CitalopramAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
ClopidogrelAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
CorticotropinMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
Cortisone acetateMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
Dabigatran etexilateMay enhance the anticoagulant effect of Anticoagulants.
DalteparinMay enhance the anticoagulant effect of Anticoagulants.
DanaparoidMay enhance the anticoagulant effect of Anticoagulants.
DapagliflozinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
DesvenlafaxineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
DiflunisalNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
DiltiazemCalcium Channel Blockers (Nondihydropyridine) may enhance the anticoagulant effect of Salicylates.
DipyridamoleAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
DisopyramideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
DulaglutideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
DuloxetineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
EmpagliflozinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
EnalaprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
EnoxaparinMay enhance the anticoagulant effect of Anticoagulants.
EptifibatideAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
EscitalopramAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
Ethacrynic acidMay diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.
EtodolacNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
ExenatideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
FenoprofenNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
FloctafenineNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
FludrocortisoneMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
FluoxetineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
FluvoxamineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
Fondaparinux sodiumMay enhance the anticoagulant effect of Anticoagulants.
FosinoprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
FurosemideMay diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.
GliclazideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
GlimepirideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
GlipizideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
GlyburideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
HeparinMay enhance the anticoagulant effect of Anticoagulants.
HyaluronidaseMay diminish the therapeutic effect of Hyaluronidase.
IbuprofenNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
IndomethacinNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
inhaled insulinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Insulin AspartMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Insulin DetemirMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Insulin GlargineMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Insulin GlulisineMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Insulin LisproMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Insulin RegularMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
KetoprofenNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
KetorolacNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
LanreotideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
LevomilnacipranAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
LinagliptinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
LiraglutideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
LisinoprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
Magnesium salicylateMay enhance the anticoagulant effect of other Salicylates.
MecaserminMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
Mefenamic acidNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
MeloxicamNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
MetforminMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
MethazolamideMay enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.
MethotrexateMay increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.
MethylprednisoloneMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
MifepristoneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
MiglitolMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
MilnacipranAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
MoexiprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
NabumetoneNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
NadroparinMay enhance the anticoagulant effect of Anticoagulants.
NaproxenNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
NateglinideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
OctreotideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
OxaprozinNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
ParoxetineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
PasireotideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PentamidineMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PerindoprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
PioglitazoneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PiroxicamNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
PralatrexateMay increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.
PramlintideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PrasugrelAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
PrednisoneMay enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.
ProbenecidMay diminish the therapeutic effect of Probenecid.
QuinaprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
QuinineMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
RamiprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
RepaglinideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
ReteplaseMay enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
RivaroxabanMay enhance the anticoagulant effect of Anticoagulants.
RosiglitazoneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SalsalateMay enhance the anticoagulant effect of other Salicylates.
SaxagliptinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SertralineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
SitagliptinMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SulfadiazineMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SulfamethoxazoleMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SulfisoxazoleMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SulindacNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
SunitinibMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
TenecteplaseMay enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.
Tiaprofenic acidNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
TicagrelorAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
TiclopidineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
TinzaparinMay enhance the anticoagulant effect of Anticoagulants.
TirofibanAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
TolazamideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
TolbutamideMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
TolmetinNSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective). Exceptions: Choline Magnesium Trisalicylate.
TopiramateMay enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.
TorasemideMay diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.
TrandolaprilMay diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF. The effects are likely dose-related. 100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.
TreprostinilTreprostinil may enhance the adverse/toxic effect of Salicylates. Bleeding may occur.
Valproic AcidMay increase the serum concentration of Valproic Acid and Derivatives.
VenlafaxineAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
VilazodoneAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
VorapaxarAgents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.
ZonisamideMay enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.
Food InteractionsNot Available

Targets

1. Prostaglandin G/H synthase 2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 2 P35354 Details

References:

  1. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. Pubmed
  2. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007 Feb;56(2):337-45. Pubmed
  3. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. Pubmed
  4. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. Pubmed
  5. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. Pubmed

2. Prostaglandin G/H synthase 1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. Pubmed
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. Pubmed
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. Pubmed
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. Pubmed
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. Pubmed
  6. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. Pubmed
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Comments
comments powered by Disqus
Drug created on July 08, 2007 11:05 / Updated on September 16, 2013 17:14